Khalid El Bairi: IDEA Awardees met with one of the Lancet’s editors
Khalid El Bairi shared a post on X:
“It was a great pleasure for the IDEA Awardees to meet with one of the Lancet’s esteemeed editors to discuss various initiatives The Lancet is developing for the global oncology community.
Thanks to ASCO for the wonderful ASCO24. ”
Source: Khalid El Bairi/X
Khalid El Bairi, founder of The Cancer Biomarkers Working Group, specializes in clinical and translational research in medical oncology. With many peer-reviewed articles, he delves into predictive and prognostic cancer biomarkers, especially for digestive and gynecological cancers like ovarian and colorectal malignancies. El Bairi holds board positions in international scientific societies such as IGCS, ESMO, ASCO, ESGO, and AACR. Serving as editor and reviewer for over 40 journals, he also educates medical and Ph.D. students on evidence-based medicine, research methodologies, and publishing ethics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023